Clinical trial
Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating…
NCT00389506 · National Institutes of Health Clinical Center (CC), NIH · Withdrawn
Key facts
| NCT number | NCT00389506 |
|---|---|
| Title | Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma |
| Official title | A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Other |
| Interventions | LMB-2 immunotoxin, cyclophosphamide, fludarabine phosphate, pharmacological study |
| Enrollment | 0 |
| Start date | Sep 1, 2006 |
| Completion | May 1, 2008 |
| First posted | Oct 19, 2006 |
| Last update posted | Mar 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: